1Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer [J]. Clin Adv Hematol Oncol, 2006,4(4) :459-468.
2Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second line chemotherapy in endometrial careinoma: a Gyneologic Ontology Group Study [J]. Gynecol Oncol, 2003,88 (3) :277 - 281.
3Ball HG,Blessing JA,Lentz SS,et al. A phase Ⅱ trail of paelitaxel in patients with advanced or recurrent adenocareinoma of the endometrium: a Gynecologic Oncology Group Study [J]. Gynecol Oncol, 1996, 62 (2):278-281.
4Katsumata N,Noda K,Nozawa S,et al. Phase Ⅱ trial of docetaxel in advanced or metastatic endometrial cancer:a Japanse Cooperative Study [J]. Br J Cancer, 2005,93(9):999-1004.
5Miller DS,Blessing JA,Lentz SS,et al. A phase Ⅱ of topotecan in patients with advanced persisitant or recurrent endometrial carcinoma: a Gynecologic Ontology Group Study [J]. Gynecol Oncol, 2002,87 (3) :247-251.
6Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in hight risk endometrial carcinoma:results of a randomized trial [J]. Br J Cancer,2006,95(3):266-271.
7RTOG9905/GOG0194. Comparison of radiation therapy with or without combination chemotherapy following surgery in treating patients with stage Ⅰ or stage Ⅱ endometrial cancer[DB/OL]. Available at http ://clinicaltrials. gov/ct/show/NCTO0006027
8Scudder SA,Liu PY,Wilezynski SP, et al. Paclitaxel and earboplatin with amifostin in advanced,recurrent, or refaetory endometrial adenocarcinoma: a phase Ⅱ study of the Southwest Oncology Group [J]. Gynecol Oncol, 2005,96 (3) : 610-615.
9Thigpen JT, Blessing JA, Disaia P J, et al. A randomized comparison of doxorubicin alone versus doxorubicine plus cyclophosphamide in management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study [J]. J Clin Oncol, 1994,12(9) : 1408- 1414.
10Thigpen JT, Brady MF, Homesley HD, et al. Phase Ⅲ trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study [J]. J Clin Oncol, 2004, 22 (19) : 3902- 3908.
3Kodama J,Seki N,Ojima Y,et al.Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus[J].Eur J Obstet Gynecol Reprod Biol,2007,131(1):76-80.
4Maggi R,Lissoni A,Spina F,et al.Adjuvant chemo-therapy VS radio therapy in high risk endometrial carcinoma:results of a randomised trial[J].Br J Cancer,2006,95(3):266-271.
5Semczuk A, Postawski K, Przadka D, et al. K-ras gene point mutations and p21ras immunostaining in human o- varian tumors [J]. Eur J Gynaecol Oncol, 2004, 25 (4) : 484-488.
6Klimcakova E, Chenard V, McGuirk S, et al. PGC-1α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply [J]. Cancer Res, 2012, 72(6) : 1538-1546.
7Lambropoulou M, Papadopoulos N, Tripsianis G, et al. Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2) :prognostic value and survival of endometrial cancer patients[J]. J Cancer Res Clin Oncol, 2010, 136 (3) :427-435.
8Ozkan C, Gumuskaya B, Yaman S, et al. ERCC1 expression in triple negative breast cancer [J]. J BUON, 2012, 17(2) :271-276.
9Deloia J A, Bhagwat N R, Darcy K M, et al. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum [ J ]. Gynecol Oncol, 2012, 126(3) :448-454.
10Bajpai D, Banerjee A, Pathak S, et al. Decreased expres- sion of DNA repair genes (XRCC1, ERCC1, ERCC2, and ERCC4) in squamous intraepithelial lesion and invasive squamous cell carcinoma of the cervix [J]. Mol Cell Biochem, 2013, 377(1-2) :45-53.
